Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17858017 | 0.92 | CHEK2 (0.32) | CHEK2KDM4E | |
| SCHEMBL19726302 | 0.90 | KDM4E (0.34) | MAPTKDM4ELMNATSHRMAPK1 | |
| SCHEMBL19726291 | 0.90 | ALDH1A1 (0.33) | MAPTCHEK2KDM4ELMNAMAPK1 | |
| SCHEMBL19726280 | 0.88 | CHEK2 (0.32) | ALOX5CHEK2 | |
| SCHEMBL25926385 | 0.86 | ALOX5 (0.37) | ALOX5MAPTPIM1CSNK2A2CSNK2B | |
| SCHEMBL19726279 | 0.86 | CHEK2 (0.36) | MAPTCHEK2KDM4E | |
| SCHEMBL19726261 | 0.86 | CHEK2 (0.31) | CHEK2 | |
| SCHEMBL19726281 | 0.86 | CHEK2 (0.31) | CHEK2 | |
| SCHEMBL17858058 | 0.85 | NPC1 (0.32) | CHEK2KDM4E | |
| SCHEMBL17850746 | 0.85 | MEN1 (0.35) | MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362241-A1 | 1-FUNCTIONALIZED DIBENZOFURANS AND DIBENZOTHIOPHENES FOR ORGANIC LIGHT EMITTING DIODES (OLEDS) | IDEMITSU KOSAN CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170362241-A1 | 1-FUNCTIONALIZED DIBENZOFURANS AND DIBENZOTHIOPHENES FOR ORGANIC LIGHT EMITTING DIODES (OLEDS) | IDEMITSU KOSAN CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362241-A1 | 1-FUNCTIONALIZED DIBENZOFURANS AND DIBENZOTHIOPHENES FOR ORGANIC LIGHT EMITTING DIODES (OLEDS) | OCIAD1, OCIAD2, DDT | ALOX5 474/4885MAPT 641/4885PIM1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.